Soligenix Receives Orphan Drug Designation for SGX945 Treatment.

Soligenix, a biopharmaceutical company, has announced that the FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behçet's Disease. This designation provides seven years of US market exclusivity and is intended to encourage the development of safe and effective therapies for rare diseases. The orphan drug designation was granted following recent Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet's Disease.

Soligenix, a biopharmaceutical company, has announced that the FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for the treatment of Behçet's Disease. This designation provides seven years of US market exclusivity and is intended to encourage the development of safe and effective therapies for rare diseases. The orphan drug designation was granted following recent Phase 2a clinical results demonstrating biological efficacy and safety in patients with Behçet's Disease [1].

Behçet's Disease is a rare autoimmune condition that affects up to 18,000 people in the US and approximately 1 million worldwide. The FDA's orphan drug designation offers significant regulatory advantages and market exclusivity, boosting Soligenix's position in the treatment of this chronic condition. The designation provides seven years of market exclusivity upon potential FDA approval, along with various financial benefits including government grants, FDA fee waivers, and tax credits.

The Phase 2a clinical trial demonstrated clinically meaningful improvements in patients with oral aphthous ulcers due to Behçet's Disease. This addresses a significant unmet medical need in the chronic autoimmune condition. The designation strengthens Soligenix's intellectual property position and regulatory pathway for SGX945, providing momentum for this program within their rare disease portfolio.

The concentration of Behçet's Disease patients in certain regions, such as 350,000 in Turkey, suggests targeted market opportunities. This designation enhances Soligenix's interaction opportunities with the FDA and potentially streamlines the approval process for orphan drugs treating serious conditions with unmet needs.

References:
[1] https://www.stocktitan.net/news/SNGX/fda-grants-soligenix-orphan-drug-designation-for-the-treatment-of-1ha7eiwia524.html